v3.26.1
Schedule of Company’s Segments Including a Reconciliation to Income Before Taxes (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Line Items]    
Total consolidated revenue $ 2,015,225 $ 1,637,185
Depreciation and amortization 142,698 234,462
Operating Segments [Member]    
Segment Reporting [Line Items]    
 Total revenue 2,028,532 1,641,685
Elimination of intersegment revenue (12,000) (4,500)
Total consolidated revenue 2,016,532 1,637,185
Cost of revenue 1,287,399 1,064,227
Sales and marketing 21,112 12,974
General and administrative 514,929 1,307,684
Depreciation and amortization 37,252 214,887
Segment profit (loss) 155,840 (15,873,319)
Other income (loss) 22,168 15,096
Interest expense (180,323) (307,839)
Other corporate expenses (1,745,504) (1,237,524)
Loss before taxes (1,747,819) (17,403,586)
Research and development   265,663
Impairment loss   14,645,069
Operating Segments [Member] | Revenue From External Customers [Member]    
Segment Reporting [Line Items]    
 Total revenue 2,016,532 1,637,185
Operating Segments [Member] | Inter Segment Revenue [Member]    
Segment Reporting [Line Items]    
 Total revenue 12,000 4,500
Fertility Clinic Services [Member]    
Segment Reporting [Line Items]    
Assets 6,238,540 10,654,643
Fertility Clinic Services [Member] | Operating Segments [Member]    
Segment Reporting [Line Items]    
 Total revenue 1,983,540 1,621,553
Cost of revenue 1,282,247 1,060,243
Sales and marketing 21,112 12,974
General and administrative 514,929 307,101
Depreciation and amortization 34,821 212,456
Segment profit (loss) 130,431 28,778
Research and development  
Impairment loss  
Fertility Clinic Services [Member] | Operating Segments [Member] | Revenue From External Customers [Member]    
Segment Reporting [Line Items]    
 Total revenue 1,983,540 1,621,553
Fertility Clinic Services [Member] | Operating Segments [Member] | Inter Segment Revenue [Member]    
Segment Reporting [Line Items]    
 Total revenue
INVOcell Device [Member]    
Segment Reporting [Line Items]    
Assets 29,809 39,534
INVOcell Device [Member] | Operating Segments [Member]    
Segment Reporting [Line Items]    
 Total revenue 44,992 20,132
Cost of revenue 5,152 3,984
Sales and marketing
General and administrative
Depreciation and amortization 2,431 2,431
Segment profit (loss) 37,409 13,717
Research and development  
Impairment loss  
INVOcell Device [Member] | Operating Segments [Member] | Revenue From External Customers [Member]    
Segment Reporting [Line Items]    
 Total revenue 32,992 15,632
INVOcell Device [Member] | Operating Segments [Member] | Inter Segment Revenue [Member]    
Segment Reporting [Line Items]    
 Total revenue $ 12,000 4,500
Therapeutics [Member]    
Segment Reporting [Line Items]    
Assets   16,942,932
Therapeutics [Member] | Operating Segments [Member]    
Segment Reporting [Line Items]    
 Total revenue  
Cost of revenue  
Sales and marketing  
General and administrative   1,000,583
Depreciation and amortization  
Segment profit (loss)   (15,911,315)
Research and development   265,663
Impairment loss   14,645,069
Therapeutics [Member] | Operating Segments [Member] | Revenue From External Customers [Member]    
Segment Reporting [Line Items]    
 Total revenue  
Therapeutics [Member] | Operating Segments [Member] | Inter Segment Revenue [Member]    
Segment Reporting [Line Items]    
 Total revenue